The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer
August 18th 2017William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.
Neoadjuvant T-DM1 Improves pCR in HER2+/HR+ Early Breast Cancer
Twelve weeks of neoadjuvant T-DM1 with or without endocrine therapy induced superior pathologic complete response compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.
Trastuzumab Combos, Novel Agents Key to Advancing HER2+ Breast Cancer Care
Experts are trying to determine whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in HER2-positive breast cancer without added toxicities.
Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer
July 13th 2017Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.
Lapatinib/Trastuzumab/AI Triplet Nearly Doubles PFS in HER2+/HR+ Metastatic Breast Cancer
The triplet combination of HER2-targeted therapy and an aromatase inhibitor improved progression-free survival by more than 5 months compared with the combination of trastuzumab (Herceptin) and an aromatase inhibitor in patients with HER2+/HR+ breast cancer.
Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer
June 29th 2017Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer
June 23rd 2017Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.
Dr. Freedman on Preventing Brain Metastases in HER2+ Breast Cancer
June 20th 2017Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses preventing brain metastases in patients with HER2-positive breast cancer.